Simtuzumab Attenuates Loxl2-Mediated Extracellular Matrix Remodeling and Preserves Cardiac Function in <i>LMNA</i> Mutation-Induced Dilated Cardiomyopathy
Taken together, our findings underscore the crucial role of Loxl2 as a therapeutic target and suggest that its inhibition could be a promising strategy to preserve cardiac function in <i>LMNA</i>-associated dilated cardiomyopathy.
Authors
- Charlotta Sophie Behrens (ORCID: https://orcid.org/0000-0001-6698-0572)
- Anne Forand (ORCID: https://orcid.org/0000-0003-4970-2372)
- Marie Kervella
- Azzouz Charrabi
- Fiorella C. Grandi (ORCID: https://orcid.org/0000-0002-1303-6710)
- Albano C. Méli (ORCID: https://orcid.org/0000-0002-1727-3027)
- A. Muchir
- Cécile Peccate (ORCID: https://orcid.org/0000-0002-4125-3616)
- Guy Brochier (ORCID: https://orcid.org/0000-0001-6241-8363)
- Ramaroson Andriantsitohaina (ORCID: https://orcid.org/0000-0002-4770-3585)
- Sonia R. Singh (ORCID: https://orcid.org/0000-0002-2996-7333)
- N M Mougenot
- Zoheir Guesmia
- Thomas Eschenhagen
Institutions
- Centre National de la Recherche Scientifique (FR)
- Inserm (FR)
- Universität Hamburg (DE)
- Délégation Paris 7 (FR)
- Sorbonne Université (FR)
- Physiologie et Médecine Expérimentale du Coeur et des Muscles (FR)
- University Medical Center Hamburg-Eppendorf (DE)
- Institut de Myologie (FR)
- German Centre for Cardiovascular Research (DE)
- FHU Neurovasc (FR)
- Centre de Recherche en Myologie
- UMS Phénotypage du petit animal (FR)
Publication Details
- Journal
- Circulation Heart Failure
- Published
- 2026-03-17
- DOI
- https://doi.org/10.1161/circheartfailure.125.013806
- Primary Topic
- Cardiomyopathy and Myosin Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00